Increased levels of miR-21 in adipose tissue in people with obesity and type 2 diabetes, which is essentially the leading clinical manifestation of MetS associated with sluggish systemic inflammation and increased adipogenic differentiation through modulation of TGF-β1 signaling. This evidence concerns the gene TGFB1 and type 2 diabetes mellitus.